About Adorial
Adorial is a Healthcare company based in High Wycombe (United Kingdom) founded in 2014, and was acquired by C4X Discovery in March 2016. Proprietary in silico genomics platform is utilized for drug discovery. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Informatics. Its legal entity is ADORIAL LTD.
Company details
Adorial is a virtual drug discovery company using a proprietary in silico genomics platform to identify novel drug targets. Adorial was spun-out from PGXIS in 2015. Offers a technology platform, Taxonomy3 for the analysis of genetic dataset and will allow broad screening for gene-gene interactions. Adorial identified 18 novel drug targets causally related to Rheumatoid Arthritis RA) using Taxonomy3. These have not been identified in any previous published genetic analysis of RA,
- Headquarters High Wycombe, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website adorial.com
- Social LinkedIn
- Acquired by C4X Discovery (Mar 2016)
- Legal Name Adorial Ltd
- Date of Incorporation 15 Dec, 2014
- Jurisdiction MANCHESTER, ENGLAND
- Net Profit-$1.27 K (USD)88as on Jul 31, 2017
- EBITDA-$1.27 K (USD)88as on Jul 31, 2017
- Investors
- Acquired byC4X Discovery
(Mar 2016)
Investors in Adorial
Adorial has secured backing from 1 investor. Prominent investors backing the company include C4X Discovery.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of optimized drug discovery and design services | 2008 | c4xdiscovery.com | Manchester, United Kingdom |
Investor details for Adorial
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Adorial
2 dated milestones of Adorial across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Adorial is founded.
- Exit Acquired by C4X Discovery.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Adorial (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Adorial
Adorial was founded in 2014.
Adorial is headquartered in High Wycombe, United Kingdom. It is registered at High Wycombe, Buckinghamshire, United Kingdom.
Adorial is a virtual drug discovery company using a proprietary in silico genomics platform to identify novel drug targets. Adorial was spun-out from PGXIS in 2015. Offers a technology platform, Taxonomy3 for the analysis of genetic dataset and will allow broad screening for gene-gene interactions. Adorial identified 18 novel drug targets causally related to Rheumatoid Arthritis RA) using Taxonomy3. These have not been identified in any previous published genetic analysis of RA,.
Adorial has 1 investor. Key investors include C4X Discovery.
Adorial operates through Adorial Ltd.
Yes. Adorial was acquired by C4X Discovery in March 2016.